Myricx Bio
Signal active
Organization
Contact Information
Overview
Myricx Bio is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyl transferase (NMT), primarily focusing on oncology and exploring potential applications across other diseases. NMT is an enzyme that modifies key proteins for cancer cell survival with specific lipids. Myricx Bio is developing a pipeline of ADCs using its NMT inhibitor (NMTi) payload platform to address critical unmet needs in oncology. It shows excellent preclinical efficacy and safety across various solid tumor antigens and cancer cell types.
About
Industries
Biotechnology, Life Science, Therapeutics
Founded
2019
Employees
1-10
Headquarters locations
Europe
Social
N/A
Profile Resume
Myricx Bio headquartered in Europe, operates in the Biotechnology, Life Science, Therapeutics sector. The company focuses on Biotechnology and has secured $2.9B in funding across 24 round(s). With a team of 1-10 employees, Myricx Bio is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Myricx Bio, raised $115.3M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
2
Investors
7
Lead Investors
0
Total Funding Amount
$121.3M
Details
2
Myricx Bio has raised a total of $121.3M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2020 | Seed | 5.9M | ||
| 2024 | Early Stage Venture | 115.3M |
Investors
Myricx Bio is funded by 18 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Myricx Bio | - | FUNDING ROUND - Myricx Bio | 115.3M |
| Abingworth | - | FUNDING ROUND - Abingworth | 115.3M |
| Myricx Bio | - | FUNDING ROUND - Myricx Bio | 115.3M |
| Eli Lilly | - | FUNDING ROUND - Eli Lilly | 115.3M |
Recent Activity
There is no recent news or activity for this profile.